[go: up one dir, main page]

WO2015170111A1 - Procédé et système de vérification - Google Patents

Procédé et système de vérification Download PDF

Info

Publication number
WO2015170111A1
WO2015170111A1 PCT/GB2015/051355 GB2015051355W WO2015170111A1 WO 2015170111 A1 WO2015170111 A1 WO 2015170111A1 GB 2015051355 W GB2015051355 W GB 2015051355W WO 2015170111 A1 WO2015170111 A1 WO 2015170111A1
Authority
WO
WIPO (PCT)
Prior art keywords
individual
location
authorised
data
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2015/051355
Other languages
English (en)
Inventor
Akshay PEER
Marc Clement
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRAKCEL Ltd
Original Assignee
TRAKCEL Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRAKCEL Ltd filed Critical TRAKCEL Ltd
Publication of WO2015170111A1 publication Critical patent/WO2015170111A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Information and communication technology [ICT] specially adapted for implementation of business processes of specific business sectors, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Social work or social welfare, e.g. community support activities or counselling services

Definitions

  • This invention relates generally to regenerative medicine, and the handling, preparation, processing or treatment of biological, therapeutic or medicinal substances for use therein.
  • it provides a mechanism for controlling the process by which the substance is handled, treated, processed or prepared, through novel verification and control techniques and architectures.
  • the invention provides the benefit of ensuring the quality of the resulting biological product, and ultimately patient safety.
  • the invention is particularly suited, but not limited to, use in autologous or allogeneic therapies.
  • RM Regenerative medicine
  • Regenerative Medicine also includes the possibility of growing tissues and organs in the laboratory and safely implanting them when the body cannot heal itself. This can potentially solve the problem of the shortage of organs available for donation, and the problem of organ transplant rejection if the organ's cells are derived from the patient's own tissue or cells.
  • RM can be broadly classed into two categories:
  • Autologous means that the therapy used for treatment is generated from the patient's body i.e. biological samples including bone marrow, blood, etc. are extracted from a given donor and then these samples are processed and administered back to the same donor.
  • the therapy can be used soon after being collected; it can also be frozen, stored and used in the future if needed.
  • Allogeneic means that the therapy used can be derived from a donor but the recipient can be different from the donor.
  • Regenerative medicine is enshrined in legislation, as more and more new regenerative medicinal therapies progress through Phase I to Phase III and eventually become commercialised, a need for a technological innovation that ensures a patient receives the correct therapeutic agent becomes imperative to protect against deleterious conditions such as host versus graft disease.
  • these therapies In order to comply with FDA and EMA regulations, these therapies must be administered by qualified professionals and ensuring donor/recipient in an controlled environment whilst providing necessary records including cell analysis, weight, tests, etc. and also a record of the 'Chain of custody' as the samples and therapeutic agents move from one facility to the next.
  • WO 2012/139090 discloses a mapping arrangement for tracking and identifying vials containing biological samples.
  • the box mapping apparatus comprises a frame for receiving a sample box of RFID-tagged sample vials, and an antenna configured to read the RFID tags so that the identify and location of each vial can be determined. This facilitates access and retrieval, so that a particular vial can be located more easily and in less time.
  • WO 2012/139090 does not teach any solution for ensuring that the contents of the vials are processed by appropriate personnel in an appropriate location.
  • US 2013/0127616 discloses a method and system for monitoring the presence of individuals at a location, such as students on a school bus.
  • the individual is identified using a code received in a RFID-UHF signal emitted by a tag carried by the individual.
  • a RFID at the location e.g. on the bus
  • Data generated as a result is transmitted to a remote server.
  • WO03/042788 describes a series of steps which comprises assigning a unique identifier to a sample, and using a reader to recognise the unique identifier so as to obtain and record time and location data showing when and where the unique identifier has been recognised from the sample. This is a passive system and merely collects information about time and location initially.
  • WO2008/1 12431 and WO2010/056287 both describe systems to track patient specimens through collection and analysis steps using RFID technology.
  • WO 2013/117928 and GB 2507019 disclose a method and system for tracking biological samples through a sequence of steps. Data is captured as the sample progresses through the steps, including data relating to the operator handling the sample and the location of the event. However, the location data is captured so as to provide a record of the event that has already taken place, in a posteriori fashion. There is no disclosure of capturing location data a priori for use in verifying whether or not the event should then be allowed to take place, and controlling the sequence of events based upon the results of that location-based verification. The location data is not used to control how the system behaves and thus the steps which are performed on the sample.
  • US 2009/0012818 discloses a method and system for ensuring that medicines are dispensed to the correct patient. It does not disclose an authentication solution for ensuring that a process or task is performed on a biological sample by an authorised person at an authorised location.
  • US 2013/0159008 discloses a solution for verifying the location of a visit made by a healthcare worker to a patient. It does not disclose a solution for controlling a process or task performed on a biological sample by ensuring that the process is conducted at the correct location and by an authorised individual.
  • a verification method comprising the step: permitting or enabling the performance of at least one predetermined task in relation to a regenerative medicine substance upon successful verification of an authorised individual and the individual's location.
  • the term 'authentication' may be used instead of 'verification' .
  • the method may be described as a method of controlling a process to be performed in relation to a biological substance, the method comprising the step:
  • the process may comprise one or more tasks. Both the process and the tasks may be predetermined and associated with the biological sample.
  • the biological sample or regenerative medicine substance may be associated with a particular source (eg a sample donor) and/or a particular recipient (eg patient to receive treatment). Therefore, it may be predetermined that a given sample is associated with a certain process, which may comprise one or more individual tasks, and that those tasks may only be performed by specified authorised individuals and within one or more specified locations.
  • Data relating to the predetermined process/tasks, authorised individuals and/or authorised locations associated with a given sample may be stored on a server.
  • the task(s), process or information relating thereto may only be communicated to or accessible by an authorised individual in an authorised location.
  • the regenerative medicine substance may be any substance or material that is to be used in a regenerative medicine process, therapy or treatment. It may be derived from a human or non human source.
  • the regenerative medicine substance may be a biological sample or therapeutic agent. It may be a medicinal product or any physiological matter. For example, it may comprise blood, tissue, stem cells, bone marrow or a medicinal/therapeutic compound. Hereinafter, for the sake of convenience, it may simply be referred to as the 'sample', 'substance' or 'agent' .
  • the individual may be permitted to perform the at least one predetermined task if, and only if, it is verified that the individual is authorised to perform the task and the individual is at an authorised location.
  • the task may be performed by the authorised individual or another individual. For example, an authorised doctor or nurse may verify his or her identity and location but the task may be performed by a trainee under the supervision of the authorised individual at the authorised location.
  • verification of the individual and his location is performed electronically.
  • 'Electronic verification' is intended to mean that the verification process is performed using one or more electronic devices having memory and processing capabilities.
  • the device may be a portable or non-portable computing device.
  • the invention provides a novel architecture for a verification system.
  • the step of permitting and/or prohibiting performance of the task may be achieved or implemented in a variety of ways. For example, permission may be provided by allowing access to a controlled resource such as a physical device and/or software system, or to data stored on a computer system or device. Additionally or alternatively, the task may be permitted by transmitting or communicating the one or more tasks to a recipient device - for example, sending the task(s) over a network to a device provided at the location.
  • a controlled resource such as a physical device and/or software system
  • the task may be permitted by transmitting or communicating the one or more tasks to a recipient device - for example, sending the task(s) over a network to a device provided at the location.
  • the task may be permitted by presenting the one or more tasks on a device e.g. by display on a screen; or it may be permitted by allowing access to a computing device or system.
  • the task may be presented in any suitable form - such as in audible form, or as a video or animation of the actions to be carried out in respect of the substance. Additionally or alternatively, it may be permitted by displaying or transmitting a notification or message indicating that the individual may proceed with the task(s).
  • the individual may be prohibited from proceeding with the process because the invention does not provide the necessary information or resource access to enable performance of the pre-determined task.
  • the invention either permits or prohibits performance of the one or more tasks based on both the identity and location of the individual. Therefore, if the individual is authorised (i.e. pre-approved) but not in an authorised location, performance of the task is prohibited. Similarly, if an unauthorised individual is in a correct (i.e. pre-approved) location for performance of the pre-determined task, performance is not permitted.
  • the invention provides a control mechanism for controlling where and by whom the regenerative medicine substance may be handled or processed.
  • the substance may only be processed by an authorised individual in an approved location, errors may be reduced or eliminated, thus preserving the integrity of the substance, as well as the health and safety of the ultimate recipient. It also ensures compliance with regulatory requirements.
  • verification of the individual and/or location is performed electronically. It may be performed using an electronic device with processing capabilities provided at the location; or it may be performed on an electronic processing device provided remotely from the location.
  • the term 'remote' is used herein to mean physically separate from and is not intended to denote any particular degree of geographical distance.
  • the method may further comprise the step of:
  • the identity data may take a variety of forms. For example, it may comprise a name and/or password, a PIN or other identifier.
  • the data may be biometric data taken or derived from the individual.
  • the identity data serves to establish the identity of the given individual.
  • the identity data may be generated by capturing data from the individual, the data being captured via manual entry or electronic entry into one or more electronic devices.
  • the identity data may be received by the electronic entry device via one or more different techniques.
  • the user may manually enter it (e.g. type it in via a mechanical keyboard).
  • it may be entered via electronic means.
  • it may be spoken by the user and captured via speech recognition software, or may be entered via a touch screen. It may be entered using optical recognition means, or by scanning something with a reading device e.g. a bar code scanner, fingerprint scanner.
  • the electronic device may be a portable device. It may be a handheld device. It may be a tablet computer, a smartphone or a laptop computer. Additionally or alternatively, it may be a desktop computer.
  • the electronic device may be referred to as an 'input device' or 'entry device' .
  • the invention is not intended to be limited with regard to the type or format of the identity data, or the means by which it is entered into the electronic input device.
  • the method may further comprise the step of:
  • the location data may be generated by capturing data relating to the current location of the individual, the data being captured via manual or electronic entry into an electronic device, or by automated location sensing means.
  • the invention is not intended to be limited with regard to the type or format of the location data, or the means by which it is entered into the electronic input device.
  • the location data may be generated by the same device used to generate the identity data, or a different device.
  • the location data may be generated by scanning a RFID or barcode label, or quick response code (known as a "QR code"). It may be manually entered as a location name or reference number; or it may be automatically computed using
  • the location computed by the automatic sensing means may need to lie within a pre-determined geographical area or region in order for it to be deemed as successfully verified. Additionally or alternatively, the data may be input by selection of a location from a list or menu displayed on a screen. Geofencing techniques may also be employed.
  • the location may be a building, a floor in a building, a room such as a clean room or a laboratory, an operating theatre etc. it may be a city or town.
  • the identity of the substance may also need to be successfully verified before performance of the at least one predetermined task may be permitted.
  • the substance may be identified by a barcode label which can be used to provide identification data to a scanning device.
  • the barcode label may be attached to a container which contains the substance.
  • Other forms of technology may be used to uniquely identify the substance, and the invention is not intended to be limited in this regard.
  • the method may comprise the step of permitting performance of the at least one predetermined task in relation to the regenerative medicine substance upon successful verification of the authorised individual and the individual's location, and the identity of the substance.
  • the method may further comprise the step of:
  • the remote computing resource may be cloud-based.
  • the remote computing resource may be a server or centralised computer.
  • the computing resource may comprise software for performing verification of the individual, substance and/or location.
  • the data may be transmitted via a wired or wireless connection. It may be transmitted via a telecommunications network. It may be transmitted via the internet. It may be encrypted. It may be transmitted from the electronic input device upon which it was entered or computed. It may be transmitted to a remote server for verification thereon.
  • the method may further comprise the steps of:
  • an electronic register of authorised individuals may be stored or maintained.
  • the register is a record of authorised individuals.
  • the register may be stored on the remote computing resource. Verification of the individual may be performed by checking the captured identity data provided by the individual against the contents of the register.
  • the register may store authorisation data relating to authorised individuals e.g. PIN, password etc. Thus, successful verification of the individual may be deemed to have occurred if the identity data generated by the input device matches an entry in the register of authorised individuals. If it does not match an entry in the register, verification of the individual is deemed to have failed.
  • the method may further comprise the step of:
  • the location data may be verified against an electronic register which stores data relating to authorised (approved) locations. Successful verification of the location may be deemed to have occurred if the location data matches an entry in the location register, and fails otherwise.
  • the stored data relating to the authorised individuals and locations may be linked. For example, an individual may only be authorised to perform a task in some but not all locations. Furthermore, an individual may only be authorised to perform certain tasks, not all task, and/or in relation to certain types of sample or agent.
  • an individual may be authorised to perform only one or more specified tasks at one or more approved locations, in respect of specified types of sample or agent.
  • One or more individuals may be mapped to (associated with) one or more pre-determined tasks which have been specified in respect of a particular substance. Therefore, for any given sample, there may be a pre-defined process which it is to undergo, and that process may only be performed by certain specified, authorised individuals and/or within specified, authorised locations.
  • the process, authorised individuals and/or authorised locations relating to a given sample may be stored electronically in a central resource. The process may be determined by a medical practitioner, administrator or other qualified person.
  • the at least one predetermined task may relate to the processing, manipulation or handling of the regenerative medicine substance.
  • the task may relate to extraction of the substance from a patient or donor; or it may concern the administration of the substance to a patient. It may relate to an allogeneic or autologous process. It may relate to chemical, manual or mechanical processing of the sample or agent.
  • the task may comprise information or instructions relating to the apparatus that must be used to perform the task. For example, it may comprise instructions to use a pipette of a certain size. The individual may be required to confirm selection and/or use of the specified apparatus eg by scanning a bar code associated with the apparatus.
  • a plurality of pre-determined tasks may be performed on or in respect of the sample.
  • the at least one predetermined task may be stored in electronic form on a server.
  • the task may form part of a task-list.
  • the at least one predetermined task may relate to custodial transfer of the biological sample or therapeutic agent from one party (e.g. individual) to another.
  • An electronic acknowledgement may be generated when custody of the substance has been transferred from one party to another.
  • An electronic record may be updated to record that custody has been transferred.
  • An alert may be generated in the event that custody of the substance cannot be transferred as a result of unsuccessful verification of identity and/or location.
  • the method may further comprise the step of:
  • recording performance data relating to the performance of the one or more predetermined tasks by the individual.
  • data may be gathered relating to the processing or handling of the substance. This can assist in maintaining a record or history of the substance or the process to which it has been subjected.
  • the method may further comprise the step:
  • data may be generated and stored to record events relating to performance of the task(s).
  • data may include identity data of one or more individuals who have performed at least one step in respect of the sample, location data of one or more individuals, the time at which at least one task was performed and/or any other relevant data.
  • the authorised individual may be a technician or operative authorised to process or handle the regenerative medicine substance, or a patient authorised to receive or donate the regenerative medicine substance.
  • the authorised individual may be someone who is authorised to take, transfer or possess custody of the sample.
  • the individual may be authorised to take, transfer or possess custody of the sample on behalf of another party such as an organisation.
  • the method may further comprise the step of:
  • the individual may need to verify his identity and/or location more than once.
  • the subsequent verifications may be requested after a predetermined period of time has elapsed, or before a subsequent task may be performed.
  • the method may further comprise the step of:
  • both an approved technician and a specified patient may need to be verified at a given location before a certain task may be performed.
  • an authorised technician may only hand over custody of a regenerative medicine substance to an authorised carrier for transfer of the substance to a different location.
  • the method may further comprise the step:
  • the method provides an improved notification system.
  • the notification may be an alert or alarm. It may be provided in visual or audible form.
  • the notification may be provided to the individual, or to a system administrator or another party.
  • the notification may be transmitted to a remote party. It may be transmitted wirelessly.
  • the notification draws attention to the fact that a verification of an individual and/or location has failed in respect of a particular task.
  • a verification system comprising one or more computing resources for performing the method described above.
  • the features described above in respect of the method may also be applicable to the
  • a computer-implemented verification system arranged to enable (permit) performance of at least one predetermined task in relation to a (particular) regenerative medicine substance upon successful verification of an authorised individual and the individual's location.
  • the invention may be defined as a control system arranged to control a process to be performed in relation to a biological substance, the system comprising:
  • the system may comprise:
  • the one or more devices being arranged to generate the data via manual entry or electronic entry.
  • the device(s) may be in communication with one or more computing resources which comprise software arranged to execute and/or facilitate the verification process (of the individual's identity and/or location). This may be wireless communication.
  • the system may comprise a remote computing resource for storing the data generated by the one or more electronic devices.
  • the resource may be remote from the location and/or electronic device.
  • the computing resource may be cloud-based.
  • the system may be arranged to enable transmission of the identity data and/or the location data to the remote computing resource.
  • the identity of the substance may also need to be successfully verified before performance of the at least one predetermined task may be permitted.
  • the substance may be identified by a barcode label which can be used to provide identification data to a scanning device.
  • the barcode label may be attached to a container which contains the substance.
  • Other forms of technology may be used to uniquely identify the substance, and the invention is not intended to be limited in this regard.
  • the system may be arranged to permit (enable) performance of the at least one predetermined task in relation to the regenerative medicine substance upon successful verification of the authorised individual and the individual's location, and the identity of the given substance.
  • the system may be arranged to:
  • the system may be arranged to:
  • the at least one predetermined task may relate to the processing, manipulation, custodial transfer or other handling of the regenerative medicine substance.
  • the individual may be able to perform the at least one predetermined task if, and only if, the system verifies that the individual is authorised to perform the task and the individual is at an authorised location. Thus, performance of the task may be prohibited upon failure of the verification of the individual's identity and/or location.
  • the at least one predetermined task may be stored in electronic form on a server.
  • the at least one predetermined task may relate to custodial transfer of the regenerative medicine substance.
  • the transfer may be from one party to another.
  • the system may be arranged to:
  • the system may be arranged to:
  • the authorised individual may be a technician or operative authorised to process or handle the regenerative medicine substance, or a patient authorised to receive or donate the regenerative medicine substance.
  • the location may be successfully verified if it is determined to be a location which has been pre-determined as being an appropriate location where the pre-determined task may be performed relation to the regenerative medicine substance.
  • the system may be arranged to:
  • the system may be arranged to:
  • the system is arranged to generate a notification upon unsuccessful verification of the individual.
  • the system may be said to provide an improved notification, alert or alarm.
  • the method may be referred to as a 'control method' because it controls the transactional process. It controls whether or not the substance can be transferred from one party to another. Custody of the substance may be transferred in physical terms (i.e. a vial containing a sample is handed over to a courier or to another technician) and/or logical (e.g. legal ownership and/or liability of the sample).
  • Transfer of the substance may be performed if, and only if, the respective locations and identities of all involved parties have been successfully verified.
  • the method may include the step of requiring the first and second individuals to provide data relating to their respective locations and identities, and then using this data to perform a verification process upon the identity /location related data.
  • This aspect of the invention may be beneficial in situations where a controlled transaction needs to occur in respect of the substance, such as transfer of custody of the substance from one party to another.
  • a controlled transaction needs to occur in respect of the substance, such as transfer of custody of the substance from one party to another.
  • This may enable a chain of custody to be recorded in respect of the substance. It may also ensure the quality of the substance because it requires the respective identities and locations all parties to be authenticated in order for the transfer to take place.
  • this aspect of the invention reduces or eliminates the likelihood of an erroneous transfer being performed. As a result, patient safety is safeguarded, as an improved regenerative medicine substance is provided.
  • the method may further comprising the steps of:
  • the electronic devices may be portable, mobile and/or handheld devices.
  • the identity data may relate to the identity of the individual.
  • the location data may relate to the current location of the individual.
  • the data may be captured via manual or electronic entry into the electronic device, or by automated sensing means.
  • the identity data, location data and electronic device(s) may be of the form described above.
  • the first and second individuals may enter their respective data via the same or different electronic devices.
  • the method may further comprising the step of:
  • the method may comprise the step of:
  • the acknowledgement may be displayed on a screen and/or other presentation device. It may take the form of a system update. It may be transmitted from one device to another. Thus, there may be a system-level acknowledgement that the transfer has taken place e.g. when an electronic record is updated. Additionally or alternatively, the transfer may be acknowledged at an individual level e.g. by informing one or more individuals that verification has been successful and that the transfer is permitted and/or has been performed. The acknowledgement may include the time of the transfer, as well as other data relating to the first/second individuals. Thus, the acknowledgement can provide a chain-of-custody for the substance, and provide assurance that the substance has been subjected to the appropriate process at the right time, by the right people, in the right location.
  • the method may further comprising the step of:
  • the system may generate an alert or alarm when verification fails.
  • the verification method fails.
  • This situation may be notified to the first and/or second individuals. Additionally or alternatively, it may be notified to another party such as a system administrator.
  • the other party may be located remotely from the first and/or second individuals.
  • the notification may be presented via a screen or other device. It may be transmitted via wired or wireless means. It may include an audible or colour coded notification. This notification ensures that potentially dangerous situations are brought to the attention of personnel who are responsible for the substance e.g. operatives, managers etc.
  • the method may further comprising the step of:
  • identity data and/or location data relating to the first and/or second individual from at least one electronic device to a remote computing resource.
  • Verification of the identity and/or location data may be performed at the remote computing resource. Additionally or alternatively, it may be performed on one or more of the electronic devices.
  • the remote computing resource may store the identity and/or location data relating to the first and/or second individual. Other data may also be stored, such as the time the identity/location data was captured and/or transmitted.
  • Successful verification of an individual's identity and/or location may be deemed to be established if the data captured using the at least one electronic device matches pre-stored data relating to one or more authorised individuals and/or locations.
  • one or more electronic registers of authorised individuals and/or locations may be stored or maintained.
  • a corresponding system may also be provided to perform these method steps.
  • the system may comprise various hardware devices arranged to perform various functions by the execution of suitably arranged software.
  • the system may be arranged to perform verification of the first and/or second individual's identity and/or location prior to recording the transfer of custody of the substance. Identification of the substance may also be required.
  • the system may comprise:
  • one or more electronic devices arranged to capture identity data and/or location data relating to the first individual
  • one or more electronic devices arranged to capture identity data and/or location data relating to the second individual.
  • These electronic devices may be as described above.
  • the software may be arranged to update an electronic record to indicate that custody of the regenerative medicine substance has been transferred from the first to the second individual.
  • the electronic record may be part of a database.
  • the database may be stored on a server.
  • the system may be arranged to:
  • the system may be arranged to:
  • the system may be arranged to:
  • identity data and/or location data relating to the first and/or second individual from at least one electronic device to a remote computing resource.
  • Successful verification of an individual's identity and/or location may be deemed to be established if the data captured using the at least one electronic device matches pre-stored data relating to one or more authorised individuals and/or locations.
  • one or more electronic registers may be maintained, storing data relating to authorised individuals and/or locations.
  • Any or all embodiments of the invention may comprise a cloud-based approach to verification.
  • Systems of the invention may comprise a cloud-based computing resource (server or database) which is in communication with the electronic devices used by the one or more individuals for verification purposes.
  • the cloud based resource may perform at least part of the verification process in respect of identity, sample and/or location.
  • the cloud based resource may provide access to one or more pre- determined tasks, and/or data. Data generated or captured during the verification process may be stored in the cloud. Data relating to performance of the task(s) may be stored in the cloud.
  • the invention may provide an improved biological sample or regenerative medicine substance because potential errors which could otherwise degrade the quality of the sample are prevented and avoided. If the (at least) two-factor verification process fails, the system does not enable the individual to perform the task.
  • Figure 1 illustrates an illustrative use of the invention, in which the individual logs or administers a blood sample from a donor.
  • Figure 2 illustrates an illustrative use of the invention, in which the chain of custody of the regenerative medicine substance is controlled by verifying the identity and location of both parties.
  • Figure 3 illustrates one way in which the invention may be implemented.
  • the invention provides a mechanism for controlling a process to which a regenerative medicine substance ('sample') may be subjected. It can be used to advantage in a variety of situations, three of which are provided for illustrative purposes below.
  • Scenario 1 Logging or administering a blood sample from a donor:
  • This log in process may comprise password- based user verification, use of an RFID card, or capture of biometric verification data (fingerprint, voice, iris and others), or a combination of these techniques.
  • Input may be received from the user via an electronic input device 4 such as a scanner, desktop computer, laptop, smartphone etc.
  • the data may be sent via the internet, a local communications channel or a telecommunications network 3 to a server or cloud based resource 2.
  • Sample collection tasks may only be authorised in specific locations or environments (operating theatres or treatment wards etc.).
  • the computing device could require GPS validation or "swiping" across a fixed transmitter such as iBeacon, Bluetooth, RFID or barcode enabled reader;
  • Verification of a patient as correct donor or recipient would require donor verification using one of, or a combination of, barcode label, RFID label or biometric recognition using fingerprint, iris or other similar technologies.
  • the system authorise the logging of the sample against the patient's data records and additional options such as shipping arrangements, lab booking, etc.
  • the user 1 is only able to perform the predetermined tasks (103) on the sample once his identity has been verified (101) and his location (102). If the user is not authorised to handle the given sample, or is not in the right location, the system prevents access to the information, software resources and/or devices required for performance of the task(s).
  • the identity of the sample may also be verified e.g. by scanning a barcode attached to a vial containing the sample.
  • the user 1 may be provided with access to a task list and/or a 'pick list' specifying the apparatus to be used for processing the substance.
  • the user logs out of the system (105).
  • the user may generate a report (104) comprising information relating to the performance of the task(s).
  • the report may be transmitted to the central computing resource 2.
  • the system 2 will not let the user 1 access his/her task list and will not allow the user to carry out any tasks until the correct user is in the correct location.
  • Scenario 2 Cell processing in a clean room or other regulated environment:
  • a cell processing task may only be authorised in specific locations or environments (grade ⁇ , B or C clean rooms). In such cases, the computing device would require GPS validation or "swiping" across a fixed transmitter such as iBeacon, Bluetooth, RFID or barcode enabled reader.
  • Verification of sample this would require sample verification using one or a combination of barcode, RFID or other labelling techniques.
  • the biological sample or therapeutic agent is verified by scanning the RFID, barcode or similar label which has a unique identification code attached to each biological sample.
  • Steps 1, 2 and 3 are complete and verified successfully, the system authorises the processing of a given biological sample (103).
  • the system must ensure that a qualified user is in the pre-defined location before permitting the user (individual) to process a certain type of biological sample/therapeutic agent. Processing of certain cells must be carried out in validated clean rooms which might be of different Grades A, B or C.
  • a user is required to verify his/her identity, his/her location and the identity of the sample/therapeutic agent to progress to the next stage. If one of these does not match the pre-defined, pre-stored information, the system 2 will not let the user undertake any further tasks and will raise an alarm for the system administrator.
  • a cell processing task may only be authorised in specific locations or environments (grade ⁇ , B or C clean rooms). In such cases, the computing device would require GPS validation or "swiping" across a fixed transmitter such as iBeacon, Bluetooth, RFID or barcode enabled reader.
  • Verification of sample this would require sample verification using one or a combination of barcode, RFID or other labelling techniques.
  • the biological sample or therapeutic agent is verified by scanning the RFID, barcode or similar label which is a unique identification code attached to each biological sample
  • Identify the other user (the receiving party) lb When transferring custody of samples or therapeutic agents between users la, lb the system 2 may prompt the first user la to capture the details of the second user lb who is accepting custody of the sample. This may be performed by logging their details in the mobile device through a username/password, RFID card swiping or barcode label swiping (with password), or biometric recognition based techniques. Once both users have been verified the system will record their identities, the identifier of the sample being transferred, and the location the sample was transferred from User la to User lb i.e. where the transfer took place.
  • the invention provides a mechanism for determining and/or recording where and when the legal and/or physical ownership, custody and/or liability of the sample(s) has transferred from one party to another.
  • the invention may be implemented by means of hardware comprising several distinct elements, and by means of a suitably programmed computer.
  • a device claim enumerating several means several of these means may be embodied by one and the same item of hardware.
  • the mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Engineering & Computer Science (AREA)
  • Business, Economics & Management (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Tourism & Hospitality (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Marketing (AREA)
  • Economics (AREA)
  • Human Resources & Organizations (AREA)
  • Child & Adolescent Psychology (AREA)
  • Strategic Management (AREA)
  • Physics & Mathematics (AREA)
  • General Business, Economics & Management (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

La présente invention concerne d'une manière générale la médecine régénérative, et des processus permettant la gestion, la préparation, le traitement ou le traitement de substances biologiques, thérapeutiques ou médicinales destinés à être utilisés dans cette dernière. De telles substances peuvent comprendre, par exemple, un tissu, du sang, des cellules souches, de la moelle osseuse, etc. En particulier, l'invention concerne un mécanisme pour commander un tel processus par l'intermédiaire de nouvelles techniques et architectures de vérification. Par commande du processus auquel la substance est soumise, l'invention préserve la qualité et l'intégrité de la substance, et protège finalement le bien-être du patient. De façon à se conformer aux réglementations, et à garantir la qualité de la substance traitée, il est souvent important que le processus soit réalisé par un individu autorisé et dans un emplacement autorisé, tel qu'une pièce d'un certain niveau de propreté ou un hôpital spécifié. L'invention exige la vérification de l'individu et de son emplacement avant d'autoriser la réalisation de la ou des tâches prédéterminées en ce qui concerne la substance. L'invention est particulièrement appropriée, mais sans y être limitée, pour une utilisation dans des thérapies autologues ou allogéniques.
PCT/GB2015/051355 2014-05-09 2015-05-08 Procédé et système de vérification Ceased WO2015170111A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1408251.5A GB2526264A (en) 2014-05-09 2014-05-09 Verification method and system
GB1408251.5 2014-05-09

Publications (1)

Publication Number Publication Date
WO2015170111A1 true WO2015170111A1 (fr) 2015-11-12

Family

ID=51032514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2015/051355 Ceased WO2015170111A1 (fr) 2014-05-09 2015-05-08 Procédé et système de vérification

Country Status (2)

Country Link
GB (1) GB2526264A (fr)
WO (1) WO2015170111A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149928A2 (fr) * 2006-06-20 2007-12-27 Choicepoint Asset Company Systèmes et procédés de chaîne de traçabilité électronique pour une utilisation avec un essai de médicament
WO2012010743A1 (fr) * 2010-07-23 2012-01-26 Nokia Corporation Procédé et appareil permettant de donner une autorisation à un utilisateur ou à un dispositif utilisateur sur la base d'informations de localisation
WO2013117928A2 (fr) * 2012-02-10 2013-08-15 Trakcel Ltd Suivi d'échantillons physiologiques ou médicaux

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020188842A1 (en) * 2001-06-06 2002-12-12 Willeby Tandy G. Client system validation by network address and associated geographic location verification
AU2002239177A1 (en) * 2002-02-08 2003-09-02 Conax As A secure locator device
US20090012818A1 (en) * 2007-07-06 2009-01-08 Valence Broadband, Inc. Dispensing medication and verifying proper medication use
US20110296513A1 (en) * 2010-05-27 2011-12-01 Farhad Kasad Location based security token
WO2013054350A2 (fr) * 2011-07-29 2013-04-18 Deshpande Bipin Prabhakar Système et procédé de vérification de transactions basée sur le lieu
US20130159008A1 (en) * 2011-12-20 2013-06-20 First Data Corporation Systems and methods for verifying healthcare visits

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007149928A2 (fr) * 2006-06-20 2007-12-27 Choicepoint Asset Company Systèmes et procédés de chaîne de traçabilité électronique pour une utilisation avec un essai de médicament
WO2012010743A1 (fr) * 2010-07-23 2012-01-26 Nokia Corporation Procédé et appareil permettant de donner une autorisation à un utilisateur ou à un dispositif utilisateur sur la base d'informations de localisation
WO2013117928A2 (fr) * 2012-02-10 2013-08-15 Trakcel Ltd Suivi d'échantillons physiologiques ou médicaux

Also Published As

Publication number Publication date
GB2526264A (en) 2015-11-25
GB201408251D0 (en) 2014-06-25

Similar Documents

Publication Publication Date Title
US20240264183A1 (en) History logging for samples of biological material
US20220180981A1 (en) Method and system for patient and biological sample identification and tracking
Dzik New technology for transfusion safety
CN112534511B (zh) 用于自动化验证医疗器械灭菌兼容性和灭菌周期选择的系统和方法
US20150039342A1 (en) Tracking of physiological or medicinal samples
US12406766B2 (en) Methods and apparatuses for managing healthcare assets and processes
US20150227945A1 (en) Immunoprofile credentialing system
US20220237535A1 (en) Method and system for electronically monitoring and recording a process in a clean space
US20190311103A1 (en) Method Performed By A Computer System for Biometric Authentication of Human Beings of a First or a Second Category
WO2015170111A1 (fr) Procédé et système de vérification
IES87259Y1 (en) A pathogen care management system and a method thereof
CN106411848A (zh) 智能取药方法及系统
CN106330933A (zh) 智能取药方法及系统
NL2012301C2 (en) Digital care communication and information system.
US20240038376A1 (en) Monitoring system responsive to multi-functional validation
Johnson View from the top: successful drug-device combination products require mastery of diverse factors, says PDA CEO
WO2020178107A1 (fr) Procédé et système de surveillance et de prévention des erreurs dans l'utilisation de produits biologiques et pharmaceutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15724748

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15724748

Country of ref document: EP

Kind code of ref document: A1